IRIS UniCatt

Rossetti, Barbara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.129
AS - Asia 1.556
EU - Europa 1.403
SA - Sud America 305
AF - Africa 89
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 4
Totale 5.492
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.034
SG - Singapore 705
CN - Cina 325
BR - Brasile 243
IT - Italia 236
FR - Francia 235
SE - Svezia 213
DE - Germania 161
VN - Vietnam 159
PL - Polonia 137
GB - Regno Unito 95
IN - India 93
IE - Irlanda 64
ID - Indonesia 52
CA - Canada 50
FI - Finlandia 48
JP - Giappone 44
ES - Italia 38
ZA - Sudafrica 35
MX - Messico 32
RU - Federazione Russa 32
UA - Ucraina 32
BD - Bangladesh 26
HK - Hong Kong 25
AR - Argentina 22
KR - Corea 20
IQ - Iraq 18
PT - Portogallo 18
AT - Austria 17
PH - Filippine 14
BE - Belgio 13
EC - Ecuador 12
LT - Lituania 12
NL - Olanda 12
TR - Turchia 12
CL - Cile 9
CM - Camerun 8
CO - Colombia 8
RO - Romania 8
IR - Iran 7
SA - Arabia Saudita 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
CH - Svizzera 6
MA - Marocco 6
TW - Taiwan 6
DZ - Algeria 5
GR - Grecia 5
UZ - Uzbekistan 5
VE - Venezuela 5
CI - Costa d'Avorio 4
EU - Europa 4
HR - Croazia 4
KE - Kenya 4
PK - Pakistan 4
AO - Angola 3
AU - Australia 3
BH - Bahrain 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
JO - Giordania 3
LB - Libano 3
LV - Lettonia 3
NG - Nigeria 3
TH - Thailandia 3
UG - Uganda 3
AZ - Azerbaigian 2
BG - Bulgaria 2
BY - Bielorussia 2
CW - ???statistics.table.value.countryCode.CW??? 2
CZ - Repubblica Ceca 2
EG - Egitto 2
HN - Honduras 2
HU - Ungheria 2
IL - Israele 2
KG - Kirghizistan 2
KZ - Kazakistan 2
ML - Mali 2
MY - Malesia 2
NI - Nicaragua 2
PA - Panama 2
PY - Paraguay 2
AL - Albania 1
AM - Armenia 1
BO - Bolivia 1
BW - Botswana 1
CG - Congo 1
GA - Gabon 1
GD - Grenada 1
GT - Guatemala 1
GY - Guiana 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
MM - Myanmar 1
MN - Mongolia 1
MQ - Martinica 1
MT - Malta 1
Totale 5.485
Salva come PNG Salva come JPEG
Città #
Singapore 376
Chandler 320
San Jose 210
Ashburn 195
Kraków 108
New York 96
Beijing 74
Milan 68
Dublin 62
Ho Chi Minh City 59
Los Angeles 54
Lauterbourg 45
Tokyo 44
Jakarta 42
Jacksonville 40
Hanoi 37
Redmond 36
San Mateo 36
The Dalles 34
Boston 33
Frankfurt am Main 31
Rome 31
Hefei 30
St Louis 30
London 29
Paris 29
Wilmington 27
Orem 25
Princeton 24
Ann Arbor 23
Houston 23
Munich 23
Helsinki 22
Marseille 22
Cattolica 21
Warsaw 21
Johannesburg 20
Moscow 19
Nanjing 19
Atlanta 17
Pune 17
Redwood City 17
Dearborn 16
Hong Kong 16
Seattle 15
Catania 14
Chicago 14
Montreal 14
Santa Clara 14
Madrid 13
São Paulo 13
Brussels 12
Dallas 12
Nuremberg 12
Brooklyn 11
Seoul 11
Council Bluffs 10
Da Nang 10
Haiphong 10
Manchester 10
Nanchang 10
Stockholm 10
Vienna 10
Fairfield 9
Kent 9
Norwalk 9
Ottawa 9
Poplar 9
Dhaka 8
Düsseldorf 8
Lawrence 8
Phoenix 8
San Francisco 8
Toronto 8
Woodbridge 8
Amsterdam 7
Brasília 7
Bremen 7
Changsha 7
Miami 7
Mumbai 7
Turku 7
Boardman 6
Buffalo 6
Charlotte 6
Cusano Milanino 6
Davao City 6
Denver 6
Hebei 6
Lappeenranta 6
Mexico City 6
Porto 6
Queens 6
Santiago 6
Turin 6
Washington 6
Bucharest 5
Guangzhou 5
Hangzhou 5
Jeddah 5
Totale 3.000
Salva come PNG Salva come JPEG
Nome #
The effects of switching from dolutegravir/abacavir/ lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomised study 506
Whole-genome sequencing reveals host factors underlying critical COVID-19 217
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 190
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 183
An explainable model of host genetic interactions linked to COVID-19 severity 164
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 162
Cognitive reserve and neuropsychological functioning in older HIV-infected people 157
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 148
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 147
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 144
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 143
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 134
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 133
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 132
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 131
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 129
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults 128
Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience 126
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 122
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 118
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 118
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 116
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 116
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 114
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 114
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 113
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 110
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 108
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 108
Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience 103
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 101
First report of spondylodiscitis due to vancomycin heteroresistant Staphylococcus capitis in immunocompetent host 100
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 100
Treatment of HCV infection with the novel NS3/4A protease inhibitors 98
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 96
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study 89
Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults 87
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors 83
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study 80
Listeria meningoencephalitis and anti-GQ1b antibody syndrome 77
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 75
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 75
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 68
Totale 5.563
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.570
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.570
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202116 0 0 0 0 0 0 0 0 0 0 12 4
2021/2022269 12 3 4 19 7 12 13 53 10 27 34 75
2022/2023887 96 105 53 116 61 100 32 77 101 70 58 18
2023/2024567 27 108 28 40 36 126 31 25 24 24 39 59
2024/2025923 30 40 91 52 106 43 52 50 99 71 155 134
2025/20262.168 331 51 122 315 464 100 367 95 115 207 1 0
Totale 5.563